Daily Sepsis Research Analysis
Three impactful sepsis papers stand out today: expert consensus guidance on rapid microbiology in critical care, a prospective ICU study defining a high-mortality ‘endotoxic septic shock’ phenotype using endotoxin activity plus organ failure, and a prospective diagnostic study showing monocyte distribution width (MDW) accurately identifies sepsis at ICU admission. Together, they advance diagnostics, risk stratification, and implementation pathways.
Summary
Three impactful sepsis papers stand out today: expert consensus guidance on rapid microbiology in critical care, a prospective ICU study defining a high-mortality ‘endotoxic septic shock’ phenotype using endotoxin activity plus organ failure, and a prospective diagnostic study showing monocyte distribution width (MDW) accurately identifies sepsis at ICU admission. Together, they advance diagnostics, risk stratification, and implementation pathways.
Research Themes
- Rapid diagnostics and implementation in critical care sepsis
- Endotoxin-driven sepsis phenotyping for trial enrichment
- Early sepsis detection using hematologic biomarkers (MDW)
Selected Articles
1. The role of rapid and advanced microbiological methods in critical care: 2025 Emanuele Russo Delphi consensus.
A multidisciplinary Delphi consensus produced 16 statements guiding the use of rapid and advanced microbiology in critical care. Key recommendations include context-specific interpretation, mandatory concurrent cultures, clinically useful <24-hour turnaround times, and particular benefits in severe sepsis, while highlighting the need for bioinformatics expertise and clinician training.
Impact: Provides actionable, consensus-based guidance for implementing rapid microbiology in ICUs, addressing interpretation, workflow, and training gaps that often limit clinical impact.
Clinical Implications: Hospitals can standardize rapid test use by pairing multiplex panels with parallel cultures, targeting <24 h turnaround, and building bioinformatics support and clinician training—especially for severe sepsis and ventilator-associated pneumonia.
Key Findings
- Consensus achieved on 16 statements guiding rapid/advanced microbiology in critical care.
- Rapid test interpretation must be contextual and accompanied by concurrent standard cultures.
- Turnaround times under 24 hours are clinically useful; digital PCR lacks sufficient evidence for routine use.
- Rapid diagnostics particularly beneficial in severe sepsis and pneumonia; bioinformatics expertise and clinician training are essential.
Methodological Strengths
- Multidisciplinary expert panel with predefined 70% consensus threshold across two Delphi rounds
- Structured literature synthesis targeting 16 prioritized clinical questions
Limitations
- Consensus-based guidance without randomized comparative effectiveness data
- Heterogeneity of technologies and lack of standardized cost-effectiveness across settings
Future Directions: Prospective studies to link rapid diagnostics implementation bundles to time-to-appropriate therapy, antimicrobial stewardship outcomes, and mortality; standardization and cost-effectiveness analyses across ICUs.
SCOPE: Interpretation of rapid and advanced microbiological test results remains nonstandardized, with no existing reference guidelines. This study aimed to analyse the existing evidence and provide expert guidance on the use of these techniques in critically ill patients. METHODS: A Delphi consensus process was conducted by a multidisciplinary panel of experts, including microbiologists, infectious disease specialists, intensivists, surgeons, and pulmonologists. Sixteen prioritized key questions were addressed via literature reviews and two Delphi rounds. Consensus was reached when 70% of the responses showed strong agreement. QUESTIONS ADDRESSED BY CONSENSUS AND RECOMMENDATIONS: Consensus was reached for all 16 statements. The key findings include the importance of interpreting rapid microbiological test results within a specific clinical context; the need for concurrent standard culture examinations alongside rapid tests to ensure the detection of all pathogens; the clinical usefulness of turnaround times <24 hours for rapid techniques; and the benefits of rapid diagnostics, particularly in severe sepsis and other severe infections. Specific recommendations were made regarding the use of rapid tests in various clinical settings (critically ill patients with suspected infection, pneumonia, and ventilator-associated pneumonia). The panel found insufficient evidence to support the routine use of digital polymerase chain reaction in various infection scenarios and concluded that clinical bioinformatics expertise is essential in microbiology laboratories that use advanced technologies. The panel also highlighted the need for basic clinician training to interpret data generated using advanced microbiological techniques. This consensus provides guidance for the appropriate use of rapid and advanced microbiological techniques for critically ill patients. However, the standardization of testing settings, interpretations, and cost-effectiveness analyses of different approaches requires further investigation. Robust preanalytical workflows and multidisciplinary clinical bioinformatics expertise are crucial for the effective implementation and interpretation of advanced techniques.
2. Organ Failure, Endotoxin Activity, and Mortality in Septic Shock.
A four-ICU prospective study shows that combining endotoxin activity (EAA ≥0.6) with high organ failure (SOFA >11 or MODS >9) identifies a septic shock subgroup with markedly elevated mortality. This ‘endotoxic septic shock’ phenotype also aligns with the δ sepsis phenotype, suggesting a biologically coherent, high-risk group for targeted anti-endotoxin trials.
Impact: Defines a pragmatic, biomarker-plus-organ dysfunction phenotype with threefold higher death risk, enabling risk enrichment and precision targeting in future trials.
Clinical Implications: ICUs can incorporate EAA with SOFA/MODS to identify endotoxic septic shock candidates for aggressive source control, early adjunctive strategies, and enrollment in anti-endotoxin interventions.
Key Findings
- Endotoxic septic shock (EAA ≥0.6 with SOFA >11 or MODS >9) had 57.1%-75% mortality depending on criteria.
- Relative risk of death for ESS vs non-ESS was 3.58 (95% CI 1.86-6.91).
- All patients with MODS >9 had high EAA (≥0.6), with 75% mortality.
- ESS patients were enriched for the δ sepsis phenotype (33.3% vs 5.8%, p=0.001).
Methodological Strengths
- Prospective multicenter ICU enrollment with predefined EAA cutoff
- Integration of biomarker (EAA) with organ failure scores (SOFA, MODS) and linkage to sepsis phenotypes
Limitations
- Modest sample size (n=90) limits precision and external validity
- Observational design precludes causal inference and does not test targeted therapy
Future Directions: Use ESS criteria for trial enrichment testing anti-endotoxin strategies; validate thresholds and clinical workflows in larger, diverse ICU cohorts.
IMPORTANCE: The relationship between endotoxin activity, organ failure, and mortality is not well understood. OBJECTIVE: To test whether the combination of endotoxin activity and organ failure identifies patients at higher risk of death from sepsis and determine the relationship to previously described sepsis phenotypes. DESIGN, SETTING, AND PARTICIPANTS: Prospective observational study in four ICUs enrolling critically ill patients with septic shock. MAIN OUTCOMES AND MEASURES: Endotoxin activity assay (EAA) results, Sequential Organ Failure Assessment (SOFA), and multiple organ dysfunction (MODS) and 28-day mortality. RESULTS: We enrolled 90 patients aged 25-95 years and set an EAA cutoff of greater than or equal to 0.6 together with SOFA greater than 11 or MODS greater than 9 to define endotoxic septic shock (ESS). At baseline mean EAA was 0.64 (sd = 0.19), whereas mean SOFA and MODS were 10.3 (sd 3.2) and 5.8 (sd 3.1), respectively. EAA greater than or equal to 0.6 and SOFA greater than 11 were present in 20 patients (23.3%) and these patients had 60% mortality. EAA greater than or equal to 0.6 and SOFA less than or equal to 11 occurred in 31 (36.0%) with mortality 12.9%. Of the 35 remaining patients with EAA less than 0.6, 29 (33.7%) had SOFA less than or equal to 11 and 5 of them (17.2%) died. Only six patients (7.0%) had EAA less than 0.6 and SOFA greater than 11 and none died (p < 0.001). All patients with MODS greater than 9 also had EAA greater than or equal to 0.6 (12 patients) with 75% mortality. EAA greater than or equal to 0.6 with MODS less than or equal to 9 occurred in 39 patients with 17.9% mortality (p < 0.001). ESS (EAA ≥ 0.6 together with SOFA > 11 or MODS > 9) occurred in 21 patients and they had significantly higher mortality (57.1% vs. 15.9%, p < 0.001) compared with non-ESS, with a relative risk for death of 3.58 (95% CI, 1.86-6.91). Among ESS patients, 7 (33.3%) had δ phenotype, whereas only 4 (5.8%) had δ among non-ESS (p = 0.001). CONCLUSIONS AND RELEVANCE: ESS compromises patients with the highest mortality rate from sepsis. Such patients are most appropriate for trials testing anti-endotoxin therapy for improving survival.
3. Usefulness of monocyte distribution width in the diagnosis of sepsis in critically ill patients.
In a prospective ICU cohort (n=344), MDW outperformed WBC, CRP, and PCT for discriminating sepsis at admission (AUC 0.877; sensitivity 80.6%, specificity 84.5 at cut-off 24) and independently associated with mortality. MDW offers a rapid, accessible biomarker for early sepsis detection and risk stratification.
Impact: Demonstrates strong diagnostic accuracy and prognostic value for a readily available hematologic parameter, supporting immediate clinical adoption.
Clinical Implications: Incorporate MDW into ICU triage and sepsis screening algorithms to trigger timely cultures and empiric therapy while refining stewardship via improved specificity.
Key Findings
- MDW was significantly higher in sepsis/septic shock vs non-sepsis (median 29.7 vs 20.4; P<.001).
- Diagnostic performance: AUC 0.877 (95% CI 0.841-0.914); sensitivity 80.6% and specificity 84.5% at cut-off 24.
- MDW independently associated with mortality after adjusting for age, sex, and SOFA (OR 1.056).
Methodological Strengths
- Prospective enrollment with head-to-head comparison against CRP, PCT, and WBC
- Clear operating characteristics (AUC, sensitivity, specificity) and adjusted mortality association
Limitations
- Single-center design may limit generalizability and cut-off calibration
- No external validation across platforms or diverse ICU populations
Future Directions: Multicenter validation of MDW cut-offs, integration into sepsis bundles with decision thresholds, and impact analyses on time-to-antibiotics and outcomes.
BACKGROUND: The incidence and mortality of sepsis remain high in the intensive care units (ICU). WBC, CRP and PCT are frequently used as tools for sepsis detection; however, none of them is specific to sepsis. The aim of the current study was to evaluate whether monocyte distribution width (MDW) is useful for early sepsis detection in critically ill patients. METHODS: Prospective cohort study was conducted in a critical care unit. MDW, CRP, PCT and WBC were evaluated for sepsis detection at the time of intensive care unit admission. RESULTS: There were 344 critically ill patients enrolled consecutively and categorized as no sepsis (200), sepsis (76) and septic shock (68). MDW in patients with sepsis diagnoses in ICU was notably higher than non-sepsis group [29.7 (24.7-35.7) vs 20.4 (18.6-22.7); P < .001] under the assumption of no mean difference between the groups. Compared to other parameters, MDW was the best to discriminate sepsis from all other conditions (area under curve [AUC], 0.877; 95% CI, 0.841 0.914), sensitivity 80.6, specificity 84.5 at a cut-off point of 24. MDW adjusted for age, sex and SOFA score was associated with mortality [OR 1.056 (95% CI: 1.004-1.09) P < .01]. CONCLUSION: The measurement of MDW is a tool that can help in the early diagnosis of sepsis in ICU settings and its value is a factor associated with the prognosis of septic patients.